



Published in final edited form as:

*Exp Hematol.* 2007 September ; 35(9): 1447–1455.

## Signals Emanating From the Membrane Proximal Region Of The Thrombopoietin Receptor (Mpl) Support Hematopoietic Stem Cell Self-Renewal

Wei Tong<sup>1,2,5</sup>, Yessenia M. Ibarra<sup>1,3</sup>, and Harvey F. Lodish<sup>1,4</sup>

<sup>1</sup>Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02142, USA

<sup>4</sup>Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

### Abstract

**(1) Objectives**—Studies using thrombopoietin  $-/-$  (TPO $-/-$ ) or TPO receptor, *mpl*  $-/-$  mice have established a critical role for TPO/*mpl* signaling in hematopoietic stem cells (HSC) development. In this study, we further dissected *mpl* signaling in both megakaryopoiesis and HSC function, using mice bearing a truncated *mpl* receptor lacking the distal 60 amino acids ( $\Delta 60$ ). This deletion removes three major signaling tyrosines on the *mpl* cytoplasmic domain, but retains the membrane proximal Box1 and Box2 domains required for JAK2 activation.

**(2) Methods**—Competitive bone marrow transplantations (BMT) and serial BMTs were performed to study HSC function. Western blot analysis was used to study TPO-stimulated signaling pathways. BM cell cultures in the presence of TPO were used to study megakaryocyte development.

**(3) Results**—In agreement with prior findings, we show that  $\Delta 60$  bone marrow (BM) cells cultured in TPO generated normal numbers of megakaryocytes, but with greatly reduced ploidy. As expected from the deletion of three signaling tyrosine residues, freshly isolated  $\Delta 60$  megakaryocytes showed marked reduction in all known TPO-stimulated signaling pathways tested, including Stat5, Stat3, Akt, and p42/44MAPK. We found that  $\Delta 60$  mice displayed normal short-term (ST-HSC) activities and marginally compromised long-term (LT-HSC) stem cell activities in primary transplantation. In addition,  $\Delta 60$  mice supported HSC self-renewal for at least two serial BMTs.

**(4) Conclusion**—Our data reveal a pivotal role for an unknown signal emanating from the membrane proximal region of the *mpl* receptor or from JAK2 itself in maintaining stem cell activity and self-renewal, in addition to its role in megakaryocytopoiesis and thrombopoiesis.

### Keywords

hematopoiesis; hematopoietic stem cells; cytokine receptors; megakaryocytes; signal transduction

<sup>5</sup>To whom correspondence should be addressed: Wei Tong, PhD, Abramson Bldg, Suite 316A, 3615 Civic Center Boulevard, Philadelphia, PA 19104-4318, Tel: 267-426-0930, Fax: 267-426-5476, Email: tongw@email.chop.edu

<sup>2</sup>Present address: Department of Pediatrics, University of Pennsylvania School of Medicine and Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA 19104-4318

<sup>3</sup>Present address: Harvard Medical School, Neuroscience Program, 220 Longwood Avenue, Boston, Massachusetts 02115, USA

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Introduction

Thrombopoietin (TPO) signaling through its receptor, *mpl*, is the primary cytokine regulating megakaryocyte development and platelet production [1,2]. Both TPO<sup>-/-</sup> and *mpl*<sup>-/-</sup> mice are severely thrombocytopenic, exhibiting only 10-15% of normal platelet levels [3,4]. They also exhibit markedly reduced megakaryocyte and CFU-Meg progenitor numbers as well as decreased megakaryocyte ploidy [5]. In addition to reduced CFU-Meg numbers, both TPO<sup>-/-</sup> and *mpl*<sup>-/-</sup> mice show a greater than 50% reduction in progenitor numbers for multiple hematopoietic lineages, including erythroid and myeloid lineages [6]. Furthermore, *mpl*<sup>-/-</sup> mice exhibit at least a 7-fold reduction in hematopoietic stem cell (HSC) activity and severe defects in supporting stem cell self-renewal [7,8]. Solar *et al* showed that in mice and humans stem cell activity in the fetal liver or bone marrow (BM) largely resides in *mpl*<sup>+</sup> stem cell subpopulations [8]. Consistently, TPO<sup>-/-</sup> mice revealed a compromised ability to support wild type stem cells, and TPO administration to TPO<sup>-/-</sup> recipients could substantially correct this defect [9]. These findings have established a critical role for TPO/*mpl* signaling in both megakaryocyte and HSC development *in vivo*. Recently, Abkowitz and Chen showed that wild type (WT) and *mpl*<sup>-/-</sup> BM cells showed similar repopulating capability when transplanted into a TPO<sup>-/-</sup> host, suggesting that TPO/*mpl* functions mostly in supporting primitive progenitor cell proliferation and preventing their differentiation [10]. Clarification of the potential role of TPO/*mpl* in HSC self-renewal and progenitor cell proliferation and differentiation, awaits further experimentation.

The *mpl* receptor belongs to the type I cytokine receptor family, which includes the erythropoietin receptor (EpoR), growth hormone receptor, and prolactin receptor. They share homology in the membrane proximal region, which includes the Box1 and Box2 domains [11]. Ligand binding induces activation of the Janus Kinase 2 (JAK2) that is associated with the receptor through Box1 and Box2 [12]. JAK2-deficient fetal livers fail to respond to TPO in forming megakaryocyte colonies, which reveals its essential role in *mpl* signaling [13].

Activated JAK2 phosphorylates tyrosine residues on the *mpl* intracellular region, thereby providing docking sites for several SH2 domain-containing downstream signaling proteins. *Mpl* activates many signaling pathways in hematopoietic cell lines and primary megakaryocytes and platelets, including Signal Transducers and Activators of Transcription 3 and 5 (Stat3 and 5), Shc/Ras/Mitogen-Activated Kinase (MAPK), and SHP2/Gab/Phosphoinositide -3 kinase (PI-3K) /Akt pathways [2]. These signaling molecules have important roles in hematopoiesis, and dysregulation of these signaling pathways are implicated in leukaemogenesis. However, the contributions of the signals initiated from JAK2 or *mpl* receptor tyrosines to stem cell function has not been dissected *in vivo*.

Mice have been generated in which a truncated *mpl* cytoplasmic domain lacking the distal 60 amino acids ( $\Delta 60$ ) replaces the wild type endogenous receptor [14]. This 60 amino acid deletion removes three major signaling tyrosines on the *mpl* cytoplasmic domain, but retains the intact membrane proximal Box 1 and Box 2 domains that are required for JAK2 activation. Luoh *et al.* showed that  $\Delta 60$  mice have normal steady-state platelet counts with normal megakaryocyte numbers and ploidy [14]. Both in cell lines and freshly- isolated platelets, this mutant  $\Delta 60$  *mpl* elicits normal activation of JAK2, but cannot activate most, if not all, known TPO-stimulated downstream signaling pathways, including Stat3, Stat5, Shc, Akt, and MAPK [14-16]. Therefore, the membrane-proximal half of the *mpl* cytoplasmic domain is sufficient to support normal megakaryocytopoiesis and thrombopoiesis, implying that some signaling pathways emanate either from this segment or directly from activated JAK2.

In contrast, the absence of the distal region of the *mpl* intracellular domain leads to a blunted response to stress or to a rapid increase in TPO levels [14]. Treatment of  $\Delta 60$  mice with a single

dose of recombinant TPO results in a smaller increase in platelet number than WT mice. Similarly,  $\Delta 60$  mice exhibit a more pronounced nadir and slower recovery from thrombocytopenia induced by myelosuppressive stress [14]. Furthermore, a single dose of TPO given immediately after lethal myelosuppressive regimens is sufficient to prevent the death of WT mice by increasing blood cells of all lineages, including platelets, white, and red blood cells [17]. Interestingly  $\Delta 60$  mice show reduced myeloprotective ability provided by TPO, although significantly improved compared to *mpl*<sup>-/-</sup> mice [18]. These data suggest that additional signals are activated by the distal receptor segment for an appropriate acute response to TPO stimulation, and that these signals play an important role during physiologic stress. However, whether these signals are important in stem cell function has not been studied.

To dissect the signaling pathways that *mpl* transduces to support stem cell activity, we studied  $\Delta 60$  knockin and *mpl* nullizygous mice. Since HSCs are difficult to culture and are scarce in numbers for biochemical studies, we analyzed the development of BM-derived megakaryocytes in response to TPO when cultured *in vitro*, and we also compared TPO-induced signaling in freshly isolated megakaryocytes from  $\Delta 60$  knockin and *mpl* nullizygous mice. In parallel we examined their stem cell repopulating capabilities and self-renewal in comparison to that of WT mice. Our results further our understanding of the signaling pathways employed by *mpl* in supporting stem cell activity, and shed light on the molecular mechanisms of cytokine receptor signaling in hematopoietic stem cells.

## Materials and Methods

### Mice

*Mpl*-deficient and  $\Delta 60$  mice were generously provided by Dr. Frederic de Sauvage (Genentech, South San Francisco, CA). The *mpl*<sup>-/-</sup> mice were backcrossed onto the C57/BL6 background for 16 generations, and  $\Delta 60$  mice for 10 generations. WT controls were purchased from Jackson Laboratories (Bar Harbor, ME), and bone marrow transplantation (BMT) recipient mice were from National Cancer Institute (NCI, Bethesda, MD).

### Bone marrow transplantation (BMT) assay

For each BMT experiment, BM cells from 6 WT C57/BL6/J, 6  $\Delta 60$ , and 6 *mpl*<sup>-/-</sup> mice were isolated and enumerated in the presence of 3% acetic acid to exclude enucleated red blood cells. Those donor cells (Ly5.2) were mixed with total BM cells from the competitor mice (Ly5.1 from NCI) at the following ratios for competitive repopulation: 1:1 (2 million cells each), 3:1 (3 million donor cells and 1 million competitor cells), and 9:1 (3.6 million donor cells and 0.4 million competitor cells). Subsequently, 4 million cells of each BM mixture were injected retro-orbitally into each lethally irradiated- recipient Ly5.1 mouse (a split dose of 10 Gy, <sup>137</sup>Cs source).

BM transplanted mice with 1:1 and 9:1 ratios were analyzed at 1, 4 and 8 months; and the ones with 3:1 ratios were used for secondary BMT. Primary BM transplanted mice with 3:1 test to competitor ratio were sacrificed at four months, and 5 million total BM cells were transplanted into each lethally-irradiated secondary recipient mice. In one set of experiments, we performed tertiary and quaternary BMTs using 20 million total BM cells for each recipient mouse.

One, four, or eight months after transplantation (as indicated in the text), the percentage of chimerism in the peripheral blood was analyzed as the fraction of donor- descended Ly5.2 cells using flow cytometry. Briefly, blood samples were treated with ammonium chloride solution (StemCell Technologies, Vancouver, BC, Canada) to lyse red blood cells, and then stained with fluorescein isothiocyanate (FITC)-conjugated anti-Ly5.2 and phycoerythrin (R-PE)-conjugated anti-Ly5.1 antibodies (1:200, BD Pharmingen, San Diego, CA). Flow cytometry

analysis (FACS) was carried out using a Becton Dickinson FACSCalibur (BD Biosciences, San Diego, CA).

### Megakaryocyte culture and quantification

Megakaryocyte culture and quantification were performed as described [19]. Briefly, BM cells were isolated, washed, and divided into four groups. Each group of cells was cultured in the serum-free media containing different concentrations of TPO (0, 1, 10, and 50 ng/ml TPO), at  $1-2 \times 10^6$  cells per mL. The serum-free media (also called megakaryocyte culture media) is composed of IMDM containing 1% Nutridoma-SP (Roche Applied Science), 2 mM L-glutamine, 100 U/mL penicillin and streptomycin, and 50  $\mu$ M  $\beta$ -mercaptoethanol. Four days later, the cells were harvested in CATCH buffer ( $\text{Ca}^{++}$  and  $\text{Mg}^{++}$  free PBS containing 3.5% BSA, 1 mM Adenosine, 2 mM Theophylline, and 0.38% Sodium Citrate) and stained with FITC-conjugated anti-CD41 antibody (1:200, BD Pharmingen). Stained megakaryocytes were subsequently labeled with 50  $\mu$ g/mL propidium iodide (PI) in 0.1% sodium citrate solution overnight, and subjected to flow cytometry.  $\text{CD41}^+$  cells with DNA content equal to or greater than 8N were quantified. These experiments were repeated independently four times. The mean megakaryocyte ploidy was calculated according to an established formula [20].

### Immunostaining and flow cytometry analysis

To measure mpl surface expression in megakaryocytes, total BM cells were stained with FITC-CD41 antibodies as described above. Cells were then stained with magnetic bead-conjugated anti-FITC antibodies followed by autoMACS purification according to the manufacturer's instructions (Miltenyi Biotec Inc., Germany). Enriched BM megakaryocytes were subsequently stained with rabbit polyclonal antibody against the mpl extracellular domain (1:1000), followed by phycoerythrin (R-PE)-conjugated anti-rabbit IgG antibody (1:400, Jackson ImmunoResearch Laboratories, West Grove, PA). To measure mpl surface expression in HSCs, lineage negative ( $\text{Lin}^-$ ) BM cells were purified using StemSep columns following the manufacturer's protocol (StemCell Technologies, Vancouver, BC, Canada).  $\text{Lin}^-$  BM cells were then stained with Allophycocyanin (APC)-conjugated c-Kit (1:200), FITC- Sca-1 (1:200, BD Pharmingen), and PE- mpl antibodies, and then subjected to FACS analysis.

### Protein lysates and western blot analysis

$\text{CD41}^+$  BM megakaryocytes were first enriched by EasySep columns (StemCell Technologies), then sorted using a MoFlo high-speed sorter (Cytomation, Fort Collins, CO). Purified  $\text{CD41}^+$  cells were starved in IMDM with 1% BSA for 2 hrs, and then stimulated with 0, 10 or 50 ng/ml TPO for 10 min in IMDM plus 0.1 % BSA. Equal numbers of cells ( $2-3 \times 10^5$ ) were used for each time point. The protein lysates were resolved on NuPAGE Novex Bis-Tris gels (Invitrogen, Carlsbad, CA) and Western blotted with indicated antibodies: anti-Stat5 (C-17) antibody (1:500, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-p-Stat5 (pTyr 694), p-Stat3 (pTyr 705), Stat3, anti- pAkt (Ser 473), Akt, p-MAPK (pThr202/Tyr204), and p42/44 MAPK antibody (1:1000, Cell Signaling Technology, Beverly, MA). These experiments were independently performed 3-5 times.

## Results

### Normal surface expression of mpl in stem cells and megakaryocytes of $\Delta 60$ mice

The truncated  $\Delta 60$  form of mpl is expressed at similar protein levels in platelets, as determined by Western blot analysis [14]. Therefore, we first compared the surface expression levels of WT mpl and  $\Delta 60$  mpl in megakaryocytes and hematopoietic stem cells. Due to the low percentage of  $\text{CD41}^+$  megakaryocytes in the BM (0.5%), we first enriched these cells from the BM of WT,  $\Delta 60$ , and  $\text{mpl}^{-/-}$  mice using FITC-conjugated anti- CD41 antibodies followed by

anti-FITC magnetic beads. After one round of bead selection, the CD41<sup>+</sup> population was usually enriched 10 fold (from 0.5% to 5% in WT mice). We then examined the surface expression level of mpl by FACS. As shown in the upper right box in Fig. 1a, in both WT and  $\Delta 60$  mice, almost all CD41<sup>+</sup> cells expressed mpl (CD41<sup>+</sup> mpl<sup>+</sup>). In contrast, in mpl<sup>-/-</sup> mice almost all CD41<sup>+</sup> cells remained mpl negative as shown in the lower right box (CD41<sup>+</sup> mpl<sup>-</sup>). Notably, mpl deficiency resulted in marked reduction in megakaryocyte numbers. Thus only 1.3% CD41<sup>+</sup> cells were obtained after the same magnetic bead enrichment (Fig. 1a). There was some non-specific staining with the mpl antibody that was also visible in mpl<sup>-/-</sup> cells, but they appeared to be CD41<sup>-</sup> (Fig. 1a).

To examine mpl surface expression on HSCs, we first purified Lineage (Lin<sup>-</sup>) BM progenitor cells from WT,  $\Delta 60$ , and mpl<sup>-/-</sup> mice, and stained them for two stem cell markers, Sca-1 and Kit, as well as mpl. As shown in Figure 1b, about 2% of Lin<sup>-</sup> BM cells were double positive for Sca-1 and Kit in both WT and  $\Delta 60$  mice, markers characteristic of hematopoietic stem cells, whereas in mpl<sup>-/-</sup> mice only 0.8% were Sca-1<sup>+</sup>Kit<sup>+</sup>. In mpl-deficient Lin<sup>-</sup>Sca-1<sup>+</sup>Kit<sup>+</sup> (LSK) cells, only background levels of mpl were observed with median fluorescence value of 10 arbitrary units (Fig. 1b). Importantly, both WT and  $\Delta 60$  LSK cells expressed similar levels of mpl with median values ranging from 60 to 70 arbitrary units (Fig. 1b). These data, therefore, support the conclusion that  $\Delta 60$  mice expressed normal levels of surface mpl on both hematopoietic stem cells and megakaryocytes.

### Reduced TPO-mediated megakaryocyte differentiation in $\Delta 60$ mice

Although  $\Delta 60$  mice exhibit normal megakaryocyte development and platelet production *in vivo*, Luoh et al., showed that fewer megakaryocytes with lower ploidy were generated from  $\Delta 60$  mice, compared to those from controls, when BM cells were cultured with a maximal concentration of TPO *in vitro* [14]. Since  $\Delta 60$  mpl, when expressed in the 32D cell line showed decreased sensitivity to TPO (Supplemental data Fig. 1S), we assessed TPO-induced proliferation and differentiation of BM-derived megakaryocytes at limiting concentrations of TPO. As shown in Fig. 2a, TPO stimulated megakaryocyte production in a dose-dependent manner, reaching maximal levels at 10-50 ng/mL TPO. The numbers of CD41<sup>+</sup> megakaryocytes with 8N and greater ploidy derived from WT and  $\Delta 60$  BM cultures were similar at all TPO concentrations (Fig. 2a). As shown in Fig. 2b, TPO increased megakaryocyte ploidy in both WT and  $\Delta 60$  BM cells, but  $\Delta 60$  megakaryocytes showed a lower ploidy than WT controls at all TPO concentrations, and the difference was more pronounced at low (1 ng/mL) than high TPO concentrations (10-50 ng/mL) (Fig. 2b). As expected, the complete absence of mpl (Mpl<sup>-/-</sup>) resulted in no increase in megakaryocyte numbers or ploidy in response to TPO (Fig. 2). Thus, megakaryocytes bearing the  $\Delta 60$  form of mpl displayed markedly reduced TPO-mediated differentiation at all TPO concentrations. Supraphysiological concentrations of TPO (50 ng/mL) cannot rescue the ploidy defect of  $\Delta 60$  megakaryocytes, even though it can increase TPO/mpl signaling strength (Fig. 3). Interestingly, TPO-mediated megakaryocyte proliferation was normal, indicating that megakaryocyte proliferation and differentiation (ploidy formation) may be regulated by different signaling pathways activated by mpl.

### Marked reduction in TPO-mediated megakaryocyte signaling in $\Delta 60$ mice

While the complete absence of mpl resulted in an 80% reduction in platelet numbers, mice bearing the  $\Delta 60$  mpl showed normal steady-state platelet levels [14].  $\Delta 60$  mice also exhibited normal numbers of megakaryocytes with normal ploidy, while mpl<sup>-/-</sup> mice had a marked reduction [14]. To investigate the signaling pathways disrupted by the truncation of the 60 C-terminal amino acids in the  $\Delta 60$  mpl mutant, we utilized freshly purified CD41<sup>+</sup> megakaryocytes and after 10 mins of TPO stimulation measured induction of p44/42MAPK, Akt, Stat3, and Stat5, which are among major signaling pathways induced by TPO (Fig. 3). Phosphorylation of Stat5 was nearly absent in  $\Delta 60$  megakaryocytes, whereas residual levels



of Stat3 phosphorylation still remained (Fig. 3a and 3b). In WT megakaryocytes, maximal activation of Akt and p42/44MAPK was achieved at 10 ng/mL TPO; in contrast,  $\Delta 60$  cells exhibited no phosphorylation of these signaling molecules at 10 ng/mL of TPO, and only residual phosphorylation could be observed at a higher TPO concentration (50 ng/mL), (Fig. 3c and 3d). The total levels of these signaling proteins were similar in cells from both types of mice (Fig. 3, bottom panels). Therefore,  $\Delta 60$  megakaryocytes displayed greatly reduced activation of several major signaling pathways induced by TPO, particularly at limiting concentrations of TPO.

### **Marginally compromised stem cell activity in $\Delta 60$ mice**

To dissect the signaling pathways that *mpl* transduces to support stem cell activity, we examined the capability of bone marrow from  $\Delta 60$  and *mpl*<sup>-/-</sup> animals to compete with normal marrow for hematopoietic reconstitution of lethally-irradiated mice. This competitive repopulation assay allows a direct and sensitive comparison of reconstitution potentials of normal,  $\Delta 60$ , and *mpl*-deficient stem cells. To this end total BM cells (Ly5.2) from WT,  $\Delta 60$ , and *mpl*<sup>-/-</sup> mice were mixed at ratios 1:1, 3:1, or 9:1 with isogenic C57/BL6 competitor cells (Ly5.1), and transplanted into lethally-irradiated Ly5.1 recipient mice. Four months after transplantation, long-term repopulating HSCs (LT-HSCs) were quantified by analyzing the percentage of chimerism in peripheral blood for donor Ly5.2 cells using flow cytometry. We expect 50% reconstitution with 1:1 test to competitor ratio, and 75% and 90% with 3:1 and 9:1 ratios, respectively. Close to the expected values, WT mice showed 42% reconstitution with a 1:1 test to competitor ratio, 71% with 3:1 and 82% with a 9:1 ratio (Fig. 4). Interestingly,  $\Delta 60$  mice showed slightly, but significantly, decreased stem cell activities at the most sensitive low test to competitor ratio: with 32% reconstitution (vs. 42%,  $p=0.01$ ) at a 1:1 and 64% (vs. 71%,  $p=0.01$ ) at a 3:1 ratio. However,  $\Delta 60$  mice exhibited normal repopulating capability (79% vs. 82%,  $p=0.5$ ) at the high test to competitor ratio (9:1), which is the least sensitive cell ratio. As reported previously, *mpl*<sup>-/-</sup> mice displayed dramatically reduced repopulation capability at all ratios compared to WT mice (Fig. 4).

Chimerism of transplanted mice was also measured at various times after transplantation to examine the activities of short-term repopulating HSCs (ST-HSCs), LT-HSCs, and the maintenance of HSCs.  $\Delta 60$  mice had no significant difference in ST-HSCs as judged by reconstitution 1 month after transplantation (Fig. 5a and b). At a 1:1 test to competitor ratio,  $\Delta 60$  BM cells exhibited a significant reduction in LT-HSC activities at 4 and 8 months compared to WT ( $p<0.05$ ) (Fig. 5a). At the least sensitive 9:1 test to competitor ratio,  $\Delta 60$  mice showed no significant difference in LT-HSC activities 4 months after transplantation, and only a small but significant decrease was observed at 8 months (Fig. 5b). In sharp contrast, *mpl*<sup>-/-</sup> BM cells showed diminished stem cell activity with time at all test to competitor ratios (Fig. 5). Even with high test to competitor (9:1) ratio, *mpl*<sup>-/-</sup> BM cells failed to compete with WT controls. Therefore,  $\Delta 60$  mice have normal ST-HSC activities and marginally compromised LT-HSC activities in primary BM transplantation, compared to WT mice. These differences between  $\Delta 60$  and WT mice only become apparent with low test to competitor ratios and long reconstitution times. Nonetheless, we conclude that  $\Delta 60$  *mpl* greatly rescued the HSC defects observed in *mpl*<sup>-/-</sup> mice.

To analyze stem cell self-renewal in  $\Delta 60$  mice, we performed serial BM transplantations. Primary BM transplanted mice with a 3:1 test to competitor ratio were sacrificed at four months and 5 million total BM cells harvested from them were transplanted into each lethally-irradiated secondary recipient mouse. Four months after secondary transplant, we detected no significant difference in repopulation from stem cells derived from  $\Delta 60$  mice compared to WT controls, using data pooled from three independent experiments (Fig. 6a). In one set of serial transplant, we furthered the analysis by performing tertiary and quaternary BMT (Fig. 6b). Taken together,

$\Delta 60$  mice supported stem cell renewal for at least two serial transplantations, and only exhibited mild decrease after 3-4 serial BMTs. In contrast, and in agreement with previous reports [7, 8], *mpl*<sup>-/-</sup> mice exhibited almost no repopulating activity at the secondary transplantation (Fig. 6).

## Discussion

Cytokine receptor signaling in HSCs has rarely been investigated. Since studies using *TPO*<sup>-/-</sup> and *mpl*<sup>-/-</sup> mice have established a critical role for *TPO*/*mpl* signaling in HSC development, we further dissected *mpl* signaling in HSC function, using  $\Delta 60$  mice bearing a truncated *mpl* receptor that lacks most if not all, functional tyrosines in the cytoplasmic domain. Using competitive BMT to analyze HSC activities and serial BMT to assess HSC self-renewal, we found that  $\Delta 60$  mice had normal ST-HSC activities and marginally compromised LT-HSC activities in primary BM transplantation, as compared to WT mice. The differences became most apparent with lower test to competitor ratios and longer reconstitution times. In addition,  $\Delta 60$  mice supported HSC self-renewal for at least two serial BMTs, indicating that *mpl* function in HSC renewal was largely normal. The results obtained from  $\Delta 60$  mice were in sharp contrast to those from *mpl*<sup>-/-</sup> mice, which showed greatly reduced ST- and LT- HSC repopulation capability after a primary transplantation and almost no repopulation after a secondary transplantation. Therefore, our data revealed a pivotal role of the membrane proximal region of the *mpl* receptor, containing Box1 and Box2, in maintaining stem cell activity and self-renewal, in addition to its role in megakaryocyte development and platelet production.

Studies in cell lines and platelets from  $\Delta 60$  mice suggest that this truncated  $\Delta 60$  *mpl* mutant lacks the three major signaling tyrosine residues that are believed to activate most, if not all, *TPO*-stimulated downstream signaling molecules, including STAT3 and STAT5, and *Shc*/*Ras*/MAPK [14-16]. We found that  $\Delta 60$  *mpl* and F5 *mpl*, with all five tyrosines mutated to phenylalanines, showed similar *TPO*-dependent cell growth: they both require 10 times more *TPO* to reach maximal growth compared to WT *mpl* (Fig. 1S and ref [15,16]). Consistent with these results, we showed that freshly- isolated megakaryocytes from  $\Delta 60$  mice exhibited severely impaired activation of Stat3, Stat5, Akt, and p42/44MAPK following *TPO* stimulation, particularly at limiting *TPO* concentrations. These studies extend studies using cell lines and in platelets from  $\Delta 60$  mice [14]. Luoh, et al., showed that fewer megakaryocytes with lower ploidy were generated from  $\Delta 60$  mice compared to those from controls, when cultured with maximal concentration of *TPO in vitro* [14]. We found that, although  $\Delta 60$  BM cells gave rise to normal numbers of megakaryocytes when cultured *in vitro* in the presence of *TPO*, the megakaryocytes showed markedly decreased ploidy at all *TPO* concentrations and particularly at limiting concentrations of *TPO*. Therefore, our data suggest that, at the cellular level, the  $\Delta 60$  form of *mpl* has an intrinsic defect in fully supporting *TPO*-dependent cell growth and differentiation.

$\Delta 60$  mice have normal steady-state platelet numbers and megakaryocyte numbers with normal ploidy [14]. In fact,  $\Delta 60$  mice have near- normal numbers of megakaryocyte progenitors, and normal levels of progenitors of all lineages, in contrast to *mpl*<sup>-/-</sup> mice [14]. However, loss of signaling from the distal region of the *mpl* intracellular domain results in a muted response to exogenous injections of *TPO* [14].  $\Delta 60$  mice exhibited a more pronounced nadir and slower recovery from thrombocytopenia induced by sublethal myelosuppression, indicating that the distal half of the *mpl* signaling domain plays a key role during physiologic stress [14]. In addition, the distal  $\Delta 60$  amino acids of the *mpl* intracellular domain is essential for the complete protection from lethal myelosuppression offered by *TPO* [18]. However, rescue of about one third of the  $\Delta 60$  mice by *TPO* indicates that the membrane-proximal intracellular domain of *mpl* induces a myeloprotective signal independent of those emanating from the distal domain of *mpl* [18]. Therefore, signals emerging from the distal *mpl* segment determine only the

quantitative, but not qualitative response to TPO, and compensatory mechanisms exist in the transgenic mouse model that disguise any overt phenotype during steady-state hematopoiesis.

The phenotypes observed in  $\Delta 60$  mpl mice are analogous to those in EpoR-HM mice [21]. These knockin mice, bearing a distally truncated EpoR that contains no cytosolic tyrosines, can sustain functional erythropoiesis capable of overcoming the embryonic lethality observed in EpoR-null mice. Steady-state erythropoiesis is largely normal in adult EpoR-HM mice. However, they show a blunted response to continual injections of Epo [21] and exhibit compromised stress-induced erythropoiesis [22], phenotypes strikingly parallel to those in  $\Delta 60$  mpl mice. Also in concordance with the phenotypes found in  $\Delta 60$  mpl mice, primary progenitors from EpoR-HM mice show a compromised ability to undergo proliferation, survival, and differentiation into erythroid cells when cultured *in vitro* with a limiting dose of Epo [22].

One explanation for the lack of an overt phenotype in steady-state hematopoiesis in  $\Delta 60$  mice is the quantitative nature of the signaling pathways employed by cytokine receptors. Perhaps the residual levels of Stat, MAPK, and Akt activation observed in  $\Delta 60$  mice, albeit low, are enough to sustain steady-state hematopoiesis, which includes HSC self-renewal and differentiation, formation and function of lineage-restricted progenitors, and thrombopoiesis. The distal region of mpl is required principally to amplify or modify the TPO-stimulated response during stress.

During bone marrow transplantation the donor-derived HSCs are thought to be subjected to significant stress. These normally quiescent cells must self-renew, proliferate and differentiate to support generation of the increased number of lineage-restricted progenitors required to generate the large numbers of myeloid and lymphoid cells required after ablation of the recipient's bone marrow. Given this stress for HSCs, it is not surprising that we observed more pronounced differences between WT and  $\Delta 60$  HSC activity after tertiary and quaternary BMTs.

The  $\Delta 60$  form of mpl lacks three major signaling tyrosines in the mpl cytoplasmic domain, but retains intact the membrane proximal Box 1 and Box 2 domains that are required for JAK2 activation [14-16]. Therefore, our results also support an alternative possible mechanism: the mpl membrane proximal domain associated with JAK2 elicits novel signaling pathways for sustaining steady-state hematopoiesis. If our biochemical studies in freshly-isolated BM megakaryocytes are indicative of the signaling pathways in HSCs activated *in vivo* in response to TPO, this suggests that known pathways such as Stats, Akt, and MAPK are not the primary TPO-stimulated signaling pathways that support normal HSC function. Alternatively, one or more as yet unidentified signaling pathways could emanate directly from JAK2, perhaps activated by the several JAK2 tyrosine residues known to become phosphorylated after cytokine receptor activation.

Thus identifying the nature of these putative mpl-receptor phospho-tyrosine (pY) independent and JAK2-associated signaling pathway(s) will be crucial in determining whether quantitatively or qualitatively different signals emanate from the membrane proximal region of the mpl cytoplasmic domain. Several signal transduction proteins, including C-myc, Vav-2 and Pim-1 have shown to be efficiently activated by EpoR and mpl missing all cytosolic tyrosine residues [23-25]. Src kinases, such as Lyn, have also been shown to be associated with EpoR and mpl, and appear important for certain biological functions [26,27]. Nonetheless, the intracellular signals that are activated by JAK2 independent of cytokine receptor tyrosine residues still remain elusive.

In summary, our results further the understanding of the signaling pathways employed by mpl in supporting stem cell activity and megakaryopoiesis. They suggest two separate domains that



regulate steady state and stress-dependent hematopoietic pathways and shed light on the molecular mechanism of cytokine receptor signaling in hematopoietic stem cells.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


### Acknowledgements

HFL is supported by NIH grants P01 HL32262 and RO1 DK067356. WT is supported by Howard Temin Career Development award from NCI (K01-CA115679). YMI is supported by an undergraduate NIH MARC grant # 5 T34 GM08303 and MIT Summer Research Program (MSRP)- funded by HHMI grant (52003736). We are grateful to Dr. Frederic de Sauvage for providing us *mpl*<sup>-/-</sup> and  $\Delta 60$  mice, and Amgen for MGDF and recombinant *mpl* extracellular domain protein to generate anti-*mpl* antibodies. We thank Mr. Ferenc Reinhardt and Michael Gershenovich for animal technical support.

### References


1. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. *Blood* 1995;86:419–431. [PubMed: 7605981]
2. Kaushansky K. Thrombopoietin: a tool for understanding thrombopoiesis. *J Thromb Haemost* 2003;1:1587–1592. [PubMed: 12871295]
3. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in *c-mpl*-deficient mice. *Science* 1994;265:1445–1447. [PubMed: 8073287]
4. de Sauvage FJ, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. *J Exp Med* 1996;183:651–656. [PubMed: 8627177]
5. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor *c-Mpl*. *Blood* 1996;87:2162–2170. [PubMed: 8630375]
6. Carver-Moore K, Broxmeyer HE, Luoh SM, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and *c-mpl*-deficient mice. *Blood* 1996;88:803–808. [PubMed: 8704234]
7. Kimura S, Roberts AW, Metcalf D, Alexander WS. Hematopoietic stem cell deficiencies in mice lacking *c-Mpl*, the receptor for thrombopoietin. *Proc Natl Acad Sci U S A* 1998;95:1195–1200. [PubMed: 9448308]
8. Solar GP, Kerr WG, Zeigler FC, et al. Role of *c-mpl* in early hematopoiesis. *Blood* 1998;92:4–10. [PubMed: 9639492]
9. Fox N, Priestley G, Papayannopoulou T, Kaushansky K. Thrombopoietin expands hematopoietic stem cells after transplantation. *J Clin Invest* 2002;110:389–394. [PubMed: 12163458]
10. Abkowitz JL, Chen J. Studies of *c-Mpl* function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones. *Blood*. 2007EPUB ahead of print
11. Watowich SS, Wu H, Socolovsky M, Klingmuller U, Constantinescu SN, Lodish HF. Cytokine receptor signal transduction and the control of hematopoietic cell development. *Annu Rev Cell Dev Biol* 1996;12:91–128. [PubMed: 8970723]
12. Drachman JG, Kaushansky K. Structure and function of the cytokine receptor superfamily. *Curr Opin Hematol* 1995;2:22–28. [PubMed: 9371968]
13. Parganas E, Wang D, Stravopodis D, et al. *Jak2* is essential for signaling through a variety of cytokine receptors. *Cell* 1998;93:385–395. [PubMed: 9590173]
14. Luoh SM, Stefanich E, Solar G, et al. Role of the distal half of the *c-Mpl* intracellular domain in control of platelet production by thrombopoietin in vivo. *Mol Cell Biol* 2000;20:507–515. [PubMed: 10611229]
15. Gurney AL, Wong SC, Henzel WJ, de Sauvage FJ. Distinct regions of *c-Mpl* cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and *Shc* phosphorylation. *Proc Natl Acad Sci U S A* 1995;92:5292–5296. [PubMed: 7777500]
16. Drachman JG, Kaushansky K. Dissecting the thrombopoietin receptor: functional elements of the *Mpl* cytoplasmic domain. *Proc Natl Acad Sci U S A* 1997;94:2350–2355. [PubMed: 9122198]

17. Pestina TI, Cleveland JL, Yang C, Zambetti GP, Jackson CW. Mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis. *Blood* 2001;98:2084–2090. [PubMed: 11567994]
18. Pestina TI, Jackson CW. Differential role of Stat5 isoforms in effecting hematopoietic recovery induced by Mpl-ligand in lethally myelosuppressed mice. *Exp Hematol* 2003;31:1198–1205. [PubMed: 14662325]
19. Tong W, Lodish HF. Lnk Inhibits Tpo-mpl Signaling and Tpo-mediated Megakaryocytopoiesis. *J Exp Med* 2004;200:569–580. [PubMed: 15337790]
20. Arriaga M, South K, Cohen JL, Mazur EM. Interrelationship between mitosis and endomitosis in cultures of human megakaryocyte progenitor cells. *Blood* 1987;69:486–492. [PubMed: 3492223]
21. Zang H, Sato K, Nakajima H, McKay C, Ney PA, Ihle JN. The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis. *Embo J* 2001;20:3156–3166. [PubMed: 11406592]
22. Li K, Menon MP, Karur VG, Hegde S, Wojchowski DM. Attenuated signaling by a phosphotyrosine-null Epo receptor form in primary erythroid progenitor cells. *Blood* 2003;102:3147–3153. [PubMed: 12869513]
23. Drachman JG, Miyakawa Y, Luthi JN, et al. Studies with chimeric Mpl/JAK2 receptors indicate that both JAK2 and the membrane-proximal domain of Mpl are required for cellular proliferation. *J Biol Chem* 2002;277:23544–23553. [PubMed: 11980901]
24. Joneja B, Wojchowski DM. Mitogenic signaling and inhibition of apoptosis via the erythropoietin receptor Box-1 domain. *J Biol Chem* 1997;272:11176–11184. [PubMed: 9111017]
25. Miura O, Miura Y, Nakamura N, et al. Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. *Blood* 1994;84:4135–4141. [PubMed: 7527668]
26. Harder KW, Quilici C, Naik E, et al. Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. *Blood* 2004;104:3901–3910. [PubMed: 15339845]
27. Lannutti BJ, Drachman JG. Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors. *Blood* 2004;103:3736–3743. [PubMed: 14726379]
28. Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. *Blood* 2005;105:4604–4612. [PubMed: 15705783]




**Figure 1. Δ60 mice expressed comparable levels of surface mpl in both megakaryocytes and stem cells similarly to WT controls**

(a) CD41<sup>+</sup> BM cells from WT, Δ60, or mpl<sup>-/-</sup> mice were first enriched using magnetic bead selection. Subsequently, the cells were stained for PE-mpl. Percentages of CD41<sup>+</sup>mpl<sup>-</sup> cells (lower right box) and CD41<sup>+</sup>mpl<sup>+</sup> cells (upper right box) are shown in each plot. (b) Lin<sup>-</sup> BM cells from WT, Δ60, or mpl<sup>-/-</sup> mice were isolated using magnetic bead purification, and stained for Sca-1, Kit, and mpl. Percentages of Lin<sup>-</sup> cells double positive for Sca-1 and Kit are shown in the upper panels. Median fluorescence levels of PE-mpl are shown in the lower panels for Lin<sup>-</sup>Sca1<sup>+</sup>Kit<sup>+</sup> (LSK) cells.



**Figure 2.  $\Delta 60$  megakaryocytes showed reduced TPO-mediated differentiation during *in vitro* megakaryocyte culture**

Total BM cells from WT mice or  $\Delta 60$  mice were cultured in different concentrations of TPO for 4 days, (a) the numbers of  $CD41^+$  megakaryocytes with 8N and greater ploidy were enumerated (mean  $\pm$  SD). (b) Mean ploidies ( $\pm$ SD) of BM-derived megakaryocytes were plotted.




### Figure 3. Markedly reduced TPO-stimulated signaling pathways in Δ60 megakaryocytes

Freshly- isolated CD41<sup>+</sup> BM megakaryocytes from WT or Δ60 mice were stimulated with 0, 10 or 50 ng/ml of TPO for 10 mins. Protein lysates from equal number of cells were subjected to Western Blotting analysis. Phosphorylation and total protein levels of Stat5 (a), Stat3 (b), p42/44MAPK and Akt (c), are shown.




### Bone Marrow Transplantation (4 months)




**Figure 4.  $\Delta 60$  mice showed slight but significant decrease in stem cell repopulating capability four months after transplantation**

BM cells from WT,  $\Delta 60$ , and  $Mpl^{-/-}$  mice were mixed at 1:1, 3:1, or 9:1 ratio with competitor cells, and transplanted into irradiated recipient mice. Chimerism of transplanted mice were measured 4 months after transplantation. Five mice per genotype per group were used in each experiment and the results were pooled from three independent experiments. Students' t-tests were carried out and the p values for the differences between  $\Delta 60$  or  $Mpl^{-/-}$  mice and WT mice are shown on the top of each bar (n=15).

**Bone marrow transplantation (1:1 ratio)**




**Bone marrow transplantation (9:1 ratio)**



**Figure 5. Δ60 mice showed decreased stem cell maintenance eight months after transplantation**  
 BM cells from WT, Δ60, and *mpl*<sup>-/-</sup> mice were mixed at 1:1 or 9:1 ratio with Ly5.1 competitor cells, and transplanted into irradiated recipient mice. Chimerism of transplanted mice were measured 1, 4, and 8 months after transplantation. (a) shows the outcome of the 1:1 test to competitor ratio, and (b) shows that of the 9:1 test to competitor ratio. Five mice per genotype were used in each experiment, and the results were pooled from three independent experiments. Students' t-tests were carried out and the p values of Δ60 comparing to WT are shown on top of each point (n=15).

### Serial Bone Marrow Transplantation (3:1 ratio)



**Figure 6. Δ60 mice show moderate defects in supporting stem cell self-renewal**

(a) Primary BM transplanted mice with 3:1 test to competitor ratio were sacrificed at four months, and 5 million total BM cells were transplanted into each secondary recipient mouse. Chimerism of the secondary transplanted mice was measured after four months. In each experiment, five mice were used in each primary and secondary transplant, and the results were pooled from three independent experiments (n=15). (b) In one experiment, the secondary transplanted mice were continued for tertiary and quaternary transplants. 20 million total BM cells were used in each tertiary and quaternary recipient mouse. Chimerism of tertiary and quaternary transplanted mice were measured at four to five months post transplant (n=10). Students' t-tests were performed and the p values of Δ60 compared to WT are shown. Since the donor cells from *mpl*<sup>-/-</sup> mice did not show any reconstitution at the secondary and tertiary transplants, this group was terminated after the tertiary BMT.